G
SRPT icon

Gainplan’s Sarepta Therapeutics SRPT Stock Holding History

Gainplan’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,000
Closed -$387K – 47
2019
Q4 		$387K Buy
+3,000
New +$303K 0.2% 34
2019
Q3 		– Sell
-2,000
Closed -$304K – 52
2019
Q2 		$304K Buy
+2,000
New +$243K 0.18% 23
2018
Q3 		– Sell
-4,000
Closed -$529K – 27
2018
Q2 		$529K Buy
+4,000
New +$377K 0.38% 8

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Gainplan's SRPT Position: Q1 2020 in Review

Gainplan sold out of Sarepta Therapeutics (SRPT) in Q1 2020, closing a stake of 3,000 shares — an estimated $387K sold.

Gainplan first reported a position in SRPT in Q2 2018 and held it in 3 quarters. The position peaked at $529K in Q2 2018. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2020.

  • Gainplan reported no remaining Sarepta Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Gainplan sold 3,000 Sarepta Therapeutics shares in Q1 2020, an estimated $387K.
  • Gainplan first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 3 quarters.
  • Gainplan's Sarepta Therapeutics position peaked at $529K in Q2 2018.
  • 366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2020.

Based on Gainplan's 13F filing for Q1 2020, filed 11 May 2020.